Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

INTRODUCTION: There have been several important developments in antiretroviral treatment in the past two years. Randomized clinical trials have been conducted to evaluate a lower dose of efavirenz (400 mg once daily). Integrase inhibitors such as dolutegravir have been approved for first-line treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitoria, Marco, Hill, Andrew M, Ford, Nathan P, Doherty, Meg, Khoo, Saye H, Pozniak, Anton L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740352/
https://www.ncbi.nlm.nih.gov/pubmed/26842728
http://dx.doi.org/10.7448/IAS.19.1.20504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740352/
https://www.ncbi.nlm.nih.gov/pubmed/26842728
http://dx.doi.org/10.7448/IAS.19.1.20504

Ejemplares similares